Search the Newsreel

Citizens cuts Spruce Biosciences stock price target on share dilution By Investing.com

Citizens has lowered its price target for Spruce Biosciences (NASDAQ:SPRB) from $150.00 to $144.00, citing potential share dilution, while maintaining a Market Outperform rating. Despite the reduction, the new target still indicates significant upside, although InvestingPro data suggests the stock may be overvalued at …

TuHURA Biosciences (HURA) Earnings Date and Reports 2026

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Consensus Rating of "Moderate Buy" by Brokerages

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has received a consensus "Moderate Buy" rating from twenty-four brokerages, with an average 12-month price target of $201.50. The company's stock opened at $156.49, has a market capitalization of $15.91 billion, and has seen significant insider selling totaling over $61 …

Benchmark raises Harvard Bioscience stock price target on revenue beat

Benchmark has increased its price target for Harvard Bioscience (NASDAQ:HBIO) to $7.50 from $6.00, maintaining a Speculative Buy rating after the company surpassed second-quarter revenue guidance. The company reported $22.7 million in revenue, exceeding both management's and consensus estimates, and subsequently raised its full-year …

Kuros Biosciences AG bestätigt Ergebnisprognose für die Jahre 2026 und 2028

Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Spruce Biosciences announced its second-quarter 2026 financial results and provided updates on its TA-ERT program for MPS IIIB. The company anticipates submitting a Biologics License Application (BLA) in Q4 2026 and initiating the TrAnsform confirmatory study and an Expanded Access Program (EAP) around the …

H.C. Wainwright cuts Aura Biosciences stock price target on strategic shift

H.C. Wainwright has lowered its price target for Aura Biosciences (NASDAQ:AURA) to $18 from $24, while maintaining a Buy rating. This adjustment comes as Aura Biosciences shifts its strategic focus and capital allocation towards ocular oncology programs, particularly after completing enrollment for its Phase …

Arcus Biosciences (RCUS) Q2 2026 Earnings Call Transcript

Sagimet Biosciences (NASDAQ:SGMT) Director Sells 20,206 Shares of Stock

Cytek Biosciences (CTKB) awards 241,416 RSUs and 127,118 options to top lawyer

Cytek Biosciences (CTKB) has granted new equity awards to its Chief Legal Officer and Secretary, Ilan Feuchtwang. These awards include 241,416 Restricted Stock Units (RSUs) and an option to purchase 127,118 shares of common stock at an exercise price of $4.66 per share. Both …

Insider Selling: Twist Bioscience (NASDAQ:TWST) CEO Sells $14,182,880.88 in Stock

Twist Bioscience CEO Emily Leproust sold 113,318 shares of company stock for over $14.18 million, reducing her ownership by 12.16%. This sale was executed under a pre-arranged Rule 10b5-1 trading plan, with the stock trading near its one-year high. Despite missing EPS estimates, analysts …

Twist Bioscience CEO Emily Leproust Executes Stock Option Exercise and Sells 113,318 Shares Under 10b5-1 Plan

Emily M. Leproust, CEO of Twist Bioscience Corp (NASDAQ:TWST), exercised stock options for 113,318 shares and subsequently sold them for a weighted average price of $125.1615 per share on August 10, 2026. These transactions were executed under a Rule 10b5-1 trading plan established in …

Aura Biosciences (AURA) files Form 3 for Chief People Officer Julie Person

Aura Biosciences, Inc. (AURA) has filed a Form 3, an initial statement of beneficial ownership, for its new Chief People Officer, Julie Person. This filing registers her status as an officer of the company, but it indicates no transactions or current holdings of company …

Forte Biosciences (NASDAQ:FBRX) Releases Earnings Results, Misses Estimates By $0.09 EPS

Forte Biosciences (NASDAQ:FBRX) announced its quarterly earnings, reporting a loss of $0.97 EPS, which missed analysts' consensus estimate of a $0.88 loss by $0.09. The company's shares are trading near their 52-week high, with significant trading volume, and institutional investors holding a large percentage …

Artelo Biosciences (ARTL) trims liabilities, boosts cash amid $5.4M H1 loss

Artelo Biosciences reported a net loss of $5.4 million for the first half of 2026 but significantly improved its liquidity and balance sheet. The company increased cash and cash equivalents to $4.2 million from $0.6 million at year-end 2025 and reduced total liabilities from …

Twist Bioscience (TWST) insider Leproust plans resale after option exercise

Twist Bioscience insider Emily M. Leproust has filed to resell up to 19,952 shares of common stock, valued at over $2.49 million, following a stock option exercise on August 12, 2026. This transaction is detailed in a Form 144 SEC filing, which also indicates …

Forte Biosciences (FBRX) to be acquired by argenx in $77-per-share cash deal

Aura Biosciences (AURA) COO Susan Abu-Absi files initial insider Form 3

Aura Biosciences (AURA) Chief Operating Officer Susan Abu-Absi has filed an initial Statement of Beneficial Ownership (Form 3) with the SEC. This filing establishes her insider status for future reporting but does not report any stock transactions or derivative positions at this time. The …

Aura Biosciences: Ocular Oncology Firm Under New Management Has Shot At Approval

Gufic Biosciences sets Sept 4 AGM; proposes ₹0.10 dividend

Can Bright Minds (TSX:DRUG) Keep Biotech Momentum Going?

Bright Minds Biosciences (TSX:DRUG) is gaining attention due to progress in its lead neuroscience program, BMB, a selective serotonin receptor-targeting candidate for difficult-to-treat seizure disorders. The company reported positive topline results from its BREAKTHROUGH study, demonstrating anti-seizure activity and a favorable safety profile, and …

Why Neurocrine Biosciences (NBIX) Stock Is Down Today

Neurocrine Biosciences (NBIX) stock is down 3.1% today, likely due to investor profit-taking and a reset of expectations following its late-July earnings release. While the company reported strong revenue growth and increased INGREZZA sales guidance, it also raised spending outlooks and highlighted the balance-sheet …

Spruce Biosciences (NASDAQ:SPRB) Issues Quarterly Earnings Results, Misses Estimates By $0.89 EPS

Spruce Biosciences (NASDAQ:SPRB) reported a quarterly loss of $6.68 per share, missing the consensus estimate of a $5.79 loss by $0.89. Despite the earnings miss, shares remained flat, and analysts maintain a "Moderate Buy" rating with an average price target of $162.62. The company …

H.C. Wainwright Maintains Aura Biosciences(AURA.US) With Buy Rating, Maintains Target Price $18

H.C. Wainwright has reiterated its Buy rating on Aura Biosciences (AURA.US) and maintained its price target of $18. This indicates the firm's continued confidence in the company's prospects. Investors will be watching for further developments from Aura Biosciences.

What's Going On With Neurocrine Biosciences Stock On Wednesday?

Neurocrine Biosciences stock experienced a dip after reports emerged of deaths and severe complications potentially linked to its drug Vykat XR, used for Prader-Willi syndrome. The FDA's adverse event data revealed seven deaths and over 100 serious events, primarily involving edema, respiratory, and cardiac …

Adage Capital discloses 9.1M Aura Biosciences (AURA) shares under shared control

Rapid Micro Biosystems (RPID) Upgraded to Buy: What Does It Mean for the Stock?

Adage Capital (DRUG) discloses 3.41% Bright Minds Biosciences stake in latest holding

Adage Capital Management, L.P. and its affiliated entities have reported a beneficial ownership of 3.41% in Bright Minds Biosciences Inc. (DRUG) through a Schedule 13G/A filing. This stake, totaling 335,000 common shares, reflects shared voting and dispositive power among the reporting persons, including Robert …

Cellectar Biosciences Q2 2026 Earnings Preview

* Cellectar Biosciences (CLRB [https://seekingalpha.com/symbol/CLRB]) is scheduled to announce Q2 earnings results on Thursday, August 13th, before market open. * The consensus EPS Estimate is -$0.52 [https://seekingalpha.com/symbol/CLRB/earnings/estimates] (+84.7% Y/Y) and the consensus Revenue Estimate is $0M * Over the last 1 year, CLRB has …

Deaths reported after treatment with Neurocrine’s approved Prader-Willi drug

Reports have emerged of seven deaths and 100 serious adverse events potentially linked to Neurocrine Biosciences’ Prader-Willi syndrome drug, Vykat, prompting concerns among clinicians and patient advocacy groups. Concurrently, Aardvark Therapeutics terminated its Phase 3 trial for ARD-101 for the same condition due to …

Why Microbix Biosystems Inc. stock is rising today

Pacira (PCRX) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Tuesday, Aug. 4, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Head of Investor Relations - Susan Mesco Chief Executive Officer - Frank Lee Chief Commercial Officer - Brendan Teehan Chief Financial Officer - Shawn Cross Chief Administrative Officer …

Aura Biosciences (NASDAQ:AURA) Shares Gap Down on Disappointing Earnings

SPRUCE BIOSCIENCES, INC. 2Q 2026: Net loss $(16.2M), EPS $(6.68) — 10-Q Summary

Spruce Biosciences, Inc. (SPRB) reported a significantly widened net loss of $(16.2M) in 2Q 2026, compared to $(2.1M) in 2Q 2025, with diluted loss per share increasing to $(6.68). The company did not report revenue but highlighted regulatory progress with TA-ERT receiving FDA Breakthrough …

Spruce Biosciences (SPRB) ramps TA-ERT spend while lifting cash to $96.3M

Spruce Biosciences (SPRB) reported an increased net loss of $28.5 million for the first half of 2026, up from $16.1 million in 2025, primarily due to higher research and development expenses for its lead asset, tralesinidase alfa (TA-ERT). Despite increased spending, the company significantly …

Prader-Willi experts flag safety risks linked to Neurocrine's rare disease drug

Experts in Prader-Willi Syndrome have raised safety concerns regarding Neurocrine's drug Vykat XR, citing serious adverse events reported in patients. Post-marketing surveillance revealed reports of edema, respiratory and cardiac complications, and seven deaths linked to the drug as of July 31st, though no causal …